The Efficacy And Safety Of PSOX Regimen As Neoadjuvant Chemotherapy For Advanced Gastric Cancer

Objective:Observe the efficacy of PSOX regimen as neoadjuvant chemotherapy for advanced gastric cancer,changes in tumor marker,chemotherapy-related adverse reactions,R0 resection rate and tumor regression,etc,and compare and analyze with DOF chemotherapy regimen to explore the progress of PSOX neoadjuvant chemotherapy regimen effectiveness and clinical safety for advanced gastric cancer.Methods:A retrospective analysis method was adopted to screen 83 patients with advanced gastric cancer admitted from October 2019 to January 2021 in the Department of Gastrointestinal Surgery,Affiliated Hospital of Qinghai University.The above gastric cancer patients were randomly assigned to PSOX group(experimental group)41 cases and DOF group(control group)42 cases.Both groups of patients received2-4 cycles of chemotherapy before the operation,and then received the D2 radical resection of gastric cancer after analysing the curative effect.To observe and compare the pathological results of the two groups of patients after neoajuvant chemotherapy,tumor marker changes,chemotherapy-related toxic and side effects,tumor regression,and R0 resection rate.Results:1.There is no statistically significant difference in general clini cal characteristics between the two groups of patients(P>0.05)and can be comp ared;2.There was no statistical difference between the two groups before and af ter AFP and CA125 chemotherapy(P>0.05),and there was statistical significan ce between PSOX group and DOF group before and after CA724 chemotherap y(P<0.05);3.The total effective rate of PSOX group was higher than that of D OF group(39.0%vs21.4%),and the disease control rate was also higher than that of DOF group(95.1%vs92.9%),the difference was not statistically significant(P>0.05);4.PSOX group and DOF group had no statistical significance in hematolo gy and non-hematology-related side effects(P>0.05),Most people of the two gro up about toxicities and side effects occurred below grade 3,and there were no death;5.The R0 resection rate in the PSOX group was higher than that in the DOF group(87.8%vs78.6%),and the PSOX group had nerve invasion(51.2%)and ascular invasion(48.8%)was slightly lower than that of the DOF group for nerv e invasion(59.5%)and vascular invasion(57.1%),and the difference was not statist ically signicant(P>0.05);6.The proportion of stage I-II after PSOX was significa ntly higher than that of the DOF group(78%vs50%),there was a statistically si gnificant difference in yp TNM between the two group(P<0.05);7.In the PSOX group,7 people(17.1%)achieved complete or subcomplete tumor regression,and 5people achieved in the DOF group the same result.The PSOX group was slight ly better than the DOF group,and the difference in tumor regression between t he two groups was statistically significant(P<0.05).Conclusions:1.The PSOX regimen is equivalent to the DOF regimen in terms of the efficacy of advanced gastric cancer,and is an alternative chemotherapy regimen;2.The toxic and side effects caused by the PSOX regimen is effective in tumor regression and reduction.Stage and R0 resection rate are better than DOF regimen.It can be used as a new chemotherapy regimen for advanced gastric cancer and is worth recommending.